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Abstract
Background: Diabetes mellitus is a major chronic disease that continues to increase significantly. One of the most
important and costly complications of diabetes are foot infections that may be colonized by pathogenic and
antimicrobial resistant bacteria, harboring several virulence factors, that could impair its successful treatment.
Staphylococcus aureus is one of the most prevalent isolate in diabetic foot infections, together with aerobes and
anaerobes.
Methods: In this study, conducted in the Lisbon area, staphylococci isolated (n = 53) from diabetic foot ulcers were
identified, genotyped and screened for virulence and antimicrobial resistance traits. Genetic relationship amongst
isolates was evaluated by pulsed-field-gel-electrophoresis with further multilocus sequence typing of the identified
pulsotypes. PCR was applied for detection of 12 virulence genes and e-test technique was performed to determine
minimal inhibitory concentration of ten antibiotics.
Results: Among the 53 isolates included in this study, 41 Staphylococcus aureus were identified. Staphylococcal
isolates were positive for intercellular adhesins icaA and icaD, negative for biofilm associated protein bap and
pantone-valentine leucocidin pvl. S. aureus quorum sensing genes agrI and agrII were identified and only one
isolate was positive for toxic shock syndrome toxin tst.
36 % of staphylococci tested were multiresistant and higher rates of resistance were obtained for ciprofloxacin and
erythromycin. Clonality analysis revealed high genomic diversity and numerous S. aureus sequence types, both
community- and hospital-acquired, belonging mostly to clonal complexes CC5 and C22, widely diffused in Portugal
nowadays.
Conclusions: This study shows that diabetic foot ulcer staphylococci are genomically diverse, present resistance to
medically important antibiotics and harbour virulence determinants. These properties suggest staphylococci can
contribute to persistence and severity of these infections, leading to treatment failure and to the possibility of
transmitting these features to other microorganisms sharing the same niche. In this context, diabetic patients may
become a transmission vehicle for microorganisms’ clones between community and clinical environments.
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Background
Foot ulcers are an increasing problem in patients with
Diabetes mellitus and infection is a frequent complica-
tion that actually constitutes the most common cause of
hospitalization in diabetic patients, often related to
lower-extremity amputation [1]. Several studies have
demonstrated that they represent an economic burden
worldwide, comparable with the costs associated with
cancer, depression, lung and musculoskeletal diseases
[2, 3]. Diabetic foot infections (DFI) are often polymicro-
bial and can be caused by several pathogens, mainly
Gram positive bacteria, being Staphylococcus the most
predominant bacterial genus, as already described [4, 5].
Staphylococcus is a frequent commensal bacteria of
human skin and mucosa, being one of the major cause
of infections in humans, ranging from minor skin infec-
tions to severe infections such as septicaemia, endocar-
ditis and osteomyelitis [6]. These bacteria may produce
several virulence factors, one of the most important be-
ing biofilm formation, which consists in adherent
bacterial populations growing inside their polymeric
structures that confer the ability of evasion to immune
system and to multiple antibiotic treatments [7]. Several
virulence genes are implicated in biofilm formation, like
icaA and icaD, responsible for the biosynthesis of poly-
saccharide intercellular adhesion (PIA) molecules, con-
taining N-acetylglucosamine, the main constituent of
the biofilm matrix in the accumulation phase [8]. A
biofilm associated protein, coded by the gene bap, was
also described as essential in biofilm production of
some Staphylococcus spp. isolated from nosocomial
infections [9].
One of the bacterial properties that allow the development
and growth of multicellular biofilm is cell communication
and signalling, in which the bacterial signals reach a
specific density or “quorum” activating regulatory genes
that control some cellular processes [10]; the S. aureus
accessory gene regulator (agr) was the first peptide signal
discovered [11].
Many virulence determinants including toxins, tissue
degrading enzymes and immune evasion factors, are
secreted by staphylococci, particularly by S. aureus [12].
Clfa is a gene responsible for causing platelet activation
through binding to fibrinogen and fibrin and for inhibiting
phagocytosis in S. aureus [13]. One of the major threats in
severe tissue necrosis is the presence of the cytotoxin
panton-valentine leukocidin (pvl), whose locus is carried
on a bacteriophage, manifesting commonly in strains
isolated from community-acquired skin and soft tissue
infections and especially from pneumonia [14]. Some
S. aureus isolates also secrete the toxic shock syndrome
toxin 1 (TSST-1), a superantigenic toxin responsible for
staphylococcal scarlet fever and toxic shock syndrome,
encoded by the tst gene [15]. S. aureus and coagulase-
negative staphylococci (CoNS) infections occur in the
community or in healthcare settings and an extremely
high percentage of these isolates are resistant to methicil-
lin. In Europe, methicillin-resistant S. aureus (MRSA) are
predominantly acquired in healthcare settings represent-
ing a major challenge to the control of antibiotic resist-
ance in hospitals [16]. Portugal is one of the European
countries presenting higher rates of MRSA in hospitals,
reaching 53.8 % according to last report data [17], and
hospital-associated MRSA (HA-MRSA) have been ex-
tensively characterized [18–20]. However, less is known
about the epidemiology of MRSA in the community
(CA-MRSA), which remains poorly understood [21].
Epidemic MRSA (EMRSA)-15 clone (ST22-IV), is cur-
rently the most predominant clone in Portuguese hospitals,
accounting for 72 % of all MRSA isolates, followed by the
NY/Japan clone (NY/JP) (ST5-II). More recently a variant
of this clone (ST105) appeared as the second most
predominant clone in Portuguese hospitals [20, 22].
In the last years the complications of DFI have raised
due to the increased rate of multidrug-resistant (MDR)
isolates, so a better knowledge of these bacteria is
necessary in order to institute an effective antibiotic
therapy [1, 5]. This study aimed to investigate the
molecular types, virulence traits and antimicrobial
susceptibility pattern of Staphylococcus spp. isolated
from diabetic foot ulcers in Portugal.
Methods
Bacterial isolates
A total of 53 staphylococci clinical isolates from diabetic
foot ulcers, belonging to 49 samples collected in a trans-
versal observational study conducted at four clinical cen-
ters in Lisbon, from January 2010 to July 2010 [4], were
used in this study. Only eight patients were hospitalized
during the collection of samples. All isolates were
processed, isolated and identified by standard methods
[4]. Each isolate corresponds to a different patient, with
the exception of following pairs, which belonged to the
same patient: S. aureus A2-1a and A2-1b, S. aureus B3-2
and B3-3, S. aureus Z1-1 and Z1-2, S. aureus Z3-1 and
Z3-2, S. aureus Z21-1 and Z-21-3, S. aureus Z27-2 and
Z27-3 and S. aureus Z33-1 and Z33-2. Although being
recovered from the same patient, such staphylococci
were included in further analysis due to the distinct col-
ony morphologies observed during isolation and purifi-
cation procedures.
Identification at species level
After inoculation in Columbia Agar + 5 % sheep blood
(Biomerieux), plates were incubated at 37 °C for 24 h.
Rapid DNA extraction was performed by suspending
four to five bacterial colonies in 100 μL of TE (10 mM
Mottola et al. Journal of Biomedical Science  (2016) 23:33 Page 2 of 10
Tris, 1 mM EDTA, pH 7.8) buffer and heating to 97 °C
for seven min. After centrifugation at 15 000 g for five
min, supernatant was collected and stored at −20 °C for
subsequent PCR screening.
Staphylococcus aureus and Staphylococcus epidermidis
identification was confirmed using a multiplex PCR
protocol described elsewhere [23]. Amplified products
were analysed by electrophoresis using 0.5X Tris-Borate-
EDTA (TBE) buffer in a 2 % agarose gel (Bioline) stained
with GreenSafe (NZYTech) and visualized by transillu-
mination under UV (Pharmacia Biotech, Thermal Im-
aging System FTI-500). NZYDNA ladder VI (NZYTech)
was used as a molecular weight marker. S. aureus ATCC
29213 and S. epidermidis ATCC 35984 were used as
PCR amplification controls.
For the remaining staphylococcal isolates, Biomerieux
API Staph galleries were used for species identification.
Screening for virulence factors
The presence of virulence determinants was evaluated
by PCR amplification using primers and protocols
previously described. Genes tested included coagulase gene
coa [24], protein A gene spa [24], adhesin genes icaA and
icaD [25], biofilm associated protein gene bap, clumping
factor a clfa [24], accessory regulators genes agrI, agrII,
agrIII and agrIV [26], toxic shock syndrome toxin 1 gene
tst and panton-valentine leukocidin pvl [27].
S. aureus ATCC 25923 was used as an amplification
control for coa, spa and clfa genes. S. epidermidis ATCC
35984 was used as icaA and icaD positive control. S.
aureus bap positive control was kindly provided by Dr.
Penadés (Cardenal Herrera University, Valencia, Spain),
agrI, agrII, agrII e agrIV control strains by Dr. Carmen
Torres (Rioja University, Spain), and tst and pvl posi-
tive controls by Dr. Michèle Bes (Centre National de
Reference des Staphylocoques, Lyon,Frande).
Evaluation of antibiotic susceptibility and detection of
mecA
Minimal inhibitory concentrations (MIC) were deter-
mined for antibiotics: cefoxitin (Fox), ceftaroline (Cpt),
ciprofloxacin (Cip), clindamycin (Cli), doxycycline (Dox),
erythromycin (Ery), gentamicin (Gen), linezolid (Lzd),
meropenem (Mem) and vancomycin (Van), by placing
e-test strips (Biomérieux) on staphylococci inoculated on
Mueller Hinton plates, incubated for 24 h at 37 °C. Test
performance was monitored using S. aureus ATCC 29213.
Detection of mecA gene was performed as previously
described [23]. Amplified products were analysed by
electrophoresis with 0.5X Tris-Borate-EDTA (TBE)
buffer in a 1.5 % agarose gel (Bioline) stained with
GreenSafe (NZYTech) and visualized by transillumination
under UV (Pharmacia Biotech, Thermal Imaging System
FTI-500). NZYDNA ladder VI (NZYTech) was used as
molecular weight marker. MRSA control strain was
kindly provided by Dr. Birgit Strommenger (Robert
Koch Institute, Germany).
Staphylococci under analysis were defined as Methi-
cillin Resistant Staphylococcus (MRS) if resistant by
cefoxitin MIC or if mecA positive [28], and as Multi-
drug Resistant (MDR) if resistant to three or more
antimicrobials belonging to different antibiotic classes
and bacterial targets [29].
Macrorestriction analysis by Pulsed-Field Gel
Electrophoresis (PFGE)
Molecular fingerprinting of staphylococci was performed
by PFGE using a CHEF-DRIII apparatus (Bio-Rad
Laboratories, San Diego, USA). Bacterial cultures were
grown overnight on Columbia agar supplemented with
5 % sheep blood (BioMérieux) and a cellular suspension
of 5 × 109 CFU/mL incorporated into 1.5 % low melt-
ing point agarose (BioRad). Discs were immersed into a
lysis solution with lysostaphin (Sigma-Aldrich) (50 μg/
ml), lysozyme (Merck) (100 μg/ml) and RNase (Roche)
(50 μg/ml) at 37 °C for 3 h. After lysis, discs were incu-
bated with proteinase K (NZYTech, Portugal) (1 mg/ml)
for 17 h at 50 °C, followed by overnight digestion with
SmaI (Takara) at 25 °C. Digested DNA was submitted to
electrophoresis in 1 % agarose gel (Seakem LE) for 23 h
at 14 °C and 6 V/cm with pulse times of five to 35 s.
Lambda Ladder PFG Marker (BioLabs) 50 μg/ml was
used as molecular weight marker. Agarose gels were
stained with ethidium bromide and visualized by trans-
illumination under UV (Pharmacia Biotech, Thermal
Imaging System FTI- 500). BioNumerics 7.5 software
(Applied Maths, Kortrijk, Belgium) was used to register
macrorestriction patterns and clustering analysis was
performed using DICE similarity coefficient and the
unweighted-pair group method with arithmetic mean
(UPGMA).
S. aureus multilocus sequence typing (MLST)
Amplification of seven housekeeping genes, including
carbamate kinase arcC, shikimate dehydrogenase aroE,
glycerol kinase glpF, guanylate kinase gmk, phosphate
acetyltransferase pta, triosephosphate isomerase tpi, and
acetyl coenzyme A acetyltransferase yqiL, was done ac-
cording to the already published protocols [30]. DNA se-
quencing was performed by Stabvida (Portugal). MLST
sequences were analysed using Bionumerics 7.5 software
(Applied Maths, Kortrijk, Belgium) and sequence types
(ST) assigned according to the S. aureus MLST database
(http://saureus.mlst.net) The eBURST algorithm, avail-
able at (http://eburst.mlst.net), was used to classify
different ST into clusters or clonal complexes (CC). A
minimum spanning tree (MST) constructed with BioNu-
merics 7.5 software (Applied Maths, Kortrijk, Belgium)
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using the concatenated seven gene fragments was also
used to evaluate the phylogenetic relationships between
isolates.
Results
Identification at species level
Among the 53 isolates included in the study, 41 were
identified as S.aureus and six as S. epidermidis by multi-
plex PCR. The API galleries identified two isolates as S.
haemolyticus, one as S. schleiferi, one as S. caprae, one
as S. simulans and one as Staphylococcus sp.
Screening for virulence factors
All isolates were positive for icaA and icaD and negative
for bap and pvl. The clfa gene was present in 70 % of
the isolates (S. aureus n = 30, S. epidermidis n = 3 and S.
sp n = 1). The S. aureus quorum sensing genes agrI and
agrII were present in 60 % and 40 % of the S. aureus
isolates respectively, and no agrII or agrIV were found.
Two S. aureus isolates did not harbour agr. With the ex-
ception of two isolates (one of which also agr negative),
all S. aureus were positive for spa. As expected, all S.
aureus isolates were coa positive, whilst only one S.
aureus was positive for tst and it was MSSA (Fig. 1).
Fig 1 Dendrogram based on SmaI-PFGE patterns of the S. aureus diabetic foot isolates. The image also displays information regarding sample
collection method, presence of virulence genes, ST/CC allocation and antimicrobial resistance profile. Fox - cefoxitin; Cip – ciprofloxacin;
Mem – meropenem; Ery – erythromycin; Cpt – ceftaroline; Cli – clindamycin; Gen – gentamicin
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Evaluation of antibiotic susceptibility and detection of mecA
All isolates were considered susceptible to vanco-
mycin (MIC ≤ 2 μg/mL) and presented the same sus-
ceptibility to linezolid (MIC ≤ 4 μg/mL) and
doxycycline (MIC ≤ 4 μg/mL) with the exception of
one methicillin-resistant S. epidermidis (MRSE) isolate
(MIC ≥ 8 μg/mL and MIC ≥ 16 μg/mL for linezolid
and doxycycline respectively), which was resistant to
six of the antibiotics tested. Ceftaroline MIC values
were ≤ 0.5 μg/mL and only two MRSA presented
MIC ≥ 4 μg/mL (ceftaroline-resistant). About 90 % of
isolates obtained MIC values for clindamycin of ≤
0.25 μg/ml and for gentamicin 4 ≤ μg/ml. About 57 %
of isolates were considered susceptible to ciprofloxa-
cin (≤4 μg/ml) and eythromycin (≤8 μg/ml), present-
ing a resistance rate of 43 %. The percentage of MDR
isolates was 36 % (Fig. 1).
Among the 41 S. aureus isolates tested, 20 were classi-
fied as MRSA (mecA positive) (Fig. 1), resulting in a
prevalence of 48.7 % among S. aureus carriers; of these,
14 were cefoxitin resistant. Among the six S. epidermidis
isolates, five were MRSE (mecA positive) and 3 were
cefoxitin resistant. The other Staphylococcus isolates
didn’t carry the mecA gene and were cefoxitin suscep-
tible. The total prevalence of methicillin-resistant iso-
lates was 47 %.
Macrorestriction analysis by Pulsed-Field Gel Electrophoresis
-PFGE-
Analysis of the dendrogram displayed in Fig. 1 led to the
selection of a 70 % similarity level for the assignment of
PFGE genomic types (pulsotypes). Hence, SmaI-macro-
restrition analysis revealed 18 distinct genomic patterns
among the 41 S. aureus isolates examined. Cluster ana-
lysis allowed grouping the isolates into five main clusters
at approximately 70 % similarity with one single member
cluster (Fig. 1). All isolates included in cluster I were
MRSA, clfa and agrI positives and belonged to ST22
(CC22). They were all resistant to ciprofloxacin and
most of them also to erythromycin. Cluster II included
only one isolate, sensitive to all antibiotics tested, clfa
and agrI positive and belonging to ST944 (CC182). The
agrII positive isolates were located only in cluster III that
was the more diverse group because included different
genoypes, most of them clfa positive belonging to CC5,
both MRSA and MSSA. These MRSA isolates showed
resistance to ciprofloxacin and erythromycin. The only
one MSSA agrII isolate that was tst positive, belonged to
this group. Cluster IV included two different genotypes,
one of which stood out (B13-1), being resistant to six of the
antibiotics tested. Cluster V included two MSSA isolates,
one clfa-agrI positive and the other clfa-agr negative.
Regarding the six S. epidermidis isolates, although the
Fig 2 Minimum spanning tree of 23 S. aureus representing the 23 different pulsotypes detected amongst the diabetic foot isolates. Nodes
indicate sequence type (ST) and their size shows the relative number of isolates for each ST. Every colour represents a distinct clonal complex
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number was inferior, four pulsotypes were observed and,
noteworthy, two different pulsotypes corresponded to two
isolates obtained from the same patient (data not shown).
S. aureus multilocus sequence typing (MLST)
High genetic diversity was revealed by MLST, as indi-
cated by the detection of 15 ST among the 23 isolates
tested (Fig. 1). Briefly, ST105 (n = 4), ST5 (n = 2), ST22
(n = 2), ST188 (n = 2 in the same patient with two differ-
ent pulsotypes), ST582 (n = 2 in the same patient with
two different pulsotypes), ST6 (n = 1), ST7 (n = 1), ST8
(n = 1), ST34 (n = 1), ST45 (n = 1), ST 72 (n = 1), ST944
(n = 1), ST1507 (n = 1), ST2246 (n = 1), ST2599 (n = 1, in
a patient with a ST105 also) (Fig. 1 and Fig. 2). Based on
sequence typing, isolates were assigned to seven MLST
CC: CC5 (n = 17, including the two different pulsotypes
found in two patients), CC22 (n = 2), CC7 (n = 1), CC8 (n
= 1), CC30 (n = 1), CC45 (n = 1), CC182 (n = 1) (Fig. 1).
MRSA lineages included ST105 (CC5), ST5 (CC5), ST22
(CC22) and ST2599 (CC5). The only MSSA tst positive
isolate belonged to ST5. The minimum spanning tree
(MST) shows the phylogenetic relationships among dia-
betic foot staphylococci (Fig. 2).
Discussion
Although previous studies reported Pseudomonas aeru-
ginosa as the most common isolate in DFU [31, 32],
many others authors from the late 1990s have shown
that Gram positive cocci are the most predominant
agents responsible for DFI, with S. aureus being the
most commonly isolated pathogen with considerably
high rates of MRSA [33, 34]. According to our results,
most isolates were identified as S. aureus (77.3 %) and
48.7 % of them considered MRSA. A study conducted by
Sotto et al. [35] reported a similar MRSA percentage but
several studies showed lower rates [5, 32, 36]. The
highest MRSA percentages in DFI, reaching 70 %, were
found in India [37].
Regarding antimicrobial susceptibility patterns, 34 %
of all staphylococcal isolates were cefoxitin resistant.
However, mecA detection is considered the gold standard
for methicillin-resistance by the CLSI [28] and 47 % of the
studied isolates were mecA positive.
Only 10 % of all staphylococci showed resistance to
meropenem but MRS isolates should be considered
resistant to other β-lactam agents, therefore including
also meropenem, because most cases of documented
MRS infections have responded poorly to β-lactam
therapy [28]. Cephalosporins with anti-MRSA activity
include ceftaroline, the active metabolite of ceftaroline
fosamil (Teflaro®, Forest Laboratories), a cephalosporin
with an in vitro broad spectrum against MRSA and most
enteric organisms [38]. Ceftaroline, approved by U.S.
Food and Drug Administration (FDA) for treatment of
acute bacterial skin infections, displayed a very good effi-
cacy in the studied isolates with MIC value ≤0.5 μg/mL,
with the exception of two resistant MRSA isolates. It is
important to refer that one MRSA isolate that was
resistant to six antibiotics studied showed sensitivity to
ceftaroline. These results are in agreement with some
recent studies that have already shown the excellent
activity of ceftaroline, both in vitro [39] and in vivo [40].
Resistance to linezolid and doxycycline was detected only
in one MRSE that showed resistance to six antibiotics.
Linezolid-resistance in S. epidermidis has been already re-
ported [41], possibly linked to a mutation in the V region of
the 23S rRNA gene. MIC values for clindamycin and genta-
micin showed susceptibility for 90 % of the isolates. These
results suggest a good efficacy of linezolid, doxycycline,
clindamycin and gentamicin for DFI treatment [42, 43].
As expected, all Staphylococcus tested were susceptible to
vancomycin; until today only one case of vancomycin-
resistant S. aureus was described in Europe, Portugal [44],
and few cases worldwide, mostly in the USA [45].
About 43 % of the isolates were resistant to ciprofloxa-
cin and erythromycin, two antibiotics largely used in
clinical practice for these type of infections. Similar rates
in ciprofloxacin and erythromycin resistance were found
in a study conducted by Gadepalli et al. [36]. With the
increasing use of quinolones in clinical practice, the de-
velopment of resistance mutants has increased [46],
pointing out for the importance to their careful adminis-
tration in clinical settings. Several genes are implicated
in macrolide resistance, especially in staphylococci and
streptococci [47], explaining the low susceptibility rates
of erythromycin in this bacterial genus.
It’s important to remember that DFI are generally
polymicrobial and the choice of antibiotic therapy
often doesn’t target specific pathogens. In fact, the
present investigation revealed a high rate (36 %) of
MDR isolates in DFI, which is in accordance with
other reports [33, 36, 48] and should represent a serious
warning for the control of this type of infections.
Virulence factors, like surface proteins and extracellular
toxins, are widely distributed among staphylococci, poten-
tially causing harmful pathogenic effects to the host [14].
In this study two S. aureus isolates were spa negative.
Some studies have already reported the absence of spa
protein with percentages of 3–5 % [49], that seems to be
linked to point mutations. In a recent study we demon-
strated that the staphylococcal isolates are able to form
biofilm [50] which may explain why all isolates tested
were positive for icaA and icaD. Otherwise, none of the
isolates carried the bap gene, already described in some
Staphylococcus spp. isolated from nosocomial infections [9].
The clfA gene was present in 70 % of our isolates
including some S. epidermidis. The presence of clfa in S.
epidermidis can be justified by the fact that in this
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species the fibrinogen-binding proteins SdrG or Fbe,
associated to adherence to fibrinogen, are highly similar
to S. aureus clumping factors A and B [51].
The only tst-positive isolate was a MSSA, agrII-posi-
tive belonging to ST5. Jarraud et al. in [27] reported that
most tst-positive S. aureus strains were associated with
both community and hospital-acquired diseases and
were all methicillin-sensitive S. aureus (MSSA).
None of our isolates was pvl-positive. The pvl locus is
strongly associated to CA-MRSA and often to agr group
III background [52]. In Portugal, it was related with one
case of CA-MRSA in 2012, belonging to the USA300
epidemic clone (ST8-IVa, t008, pvl positive), the pre-
dominant CA-MRSA clone in USA at present [53]. The
USA300 is a rare clone in Europe and its low prevalence
in Portugal was expected [56].
The contribution of the agr system to S. aureus viru-
lence by gene regulation has already been described, as
well as the association of a particular agr type in clinical
isolates harbouring important virulence factors [54]. The
agr group I was identified in the majority of the analysed
staphylococci, followed by agrII, as previously reported
in numerous other studies [27, 55]. Neither agrIII nor
agrIV were observed. Two S. aureus isolates were agr-
negative, but it is known that these variants can occur
both in vivo and in vitro [56].
The virulence profile of the studied DFI isolates was
more similar to CA-MRS than HA-MRS strains. This is
an unusual finding, considering that diabetic patients
attend frequently healthcare facilities and may suggest
an increasing lack of barrier between both settings:
hospital and community.
Sotto et al. in [35] demonstrated that the virulence
gene profiles of DFI S. aureus isolates enables to distin-
guish the grade of ulcers and to predict its outcome;
more knowledge about the virulence features of DFI
isolates would be very helpful in establishing a more ac-
curate diagnosis and consequently an adequate therapy.
PFGE genomic typing demonstrated a high diversity of
clones, detecting 18 S. aureus and four S. epidermidis
pulsotypes, respectively. According to Tenover et al.
1995 [57], it is highly probable that S. aureus isolates
grouping in the same pulsotype with 100 % similarity
belong to the same ST, as determined by MLST. The
correlation between PFGE and MLST showed that PFGE
cluster I was the most homogeneous cluster, including
only MRSA ST22 (CC22) isolates, the most common ST
observed in this study. Portugal is the European country
with the highest rate of MRSA (54.6 %) [3] and CC22 is
a common and widespread clonal group from which dif-
ferent MRSA have emerged, like the pandemic ST22-
MRSA-IV (UK-EMRSA 15), present in hospitals as well
as in outpatients [58]. CC22 represents a major clone in
Portugal hospitals since 2001, having replace the Brazilian
clone [59], and its prevalence has increased to more
than 70 % of MRSA, likewise to what is observed in
the United Kingdom, where this clone is believed to
have originated [22]. All ST22 isolates were positive
for clfa, another virulent factor that confers pathogenicity,
and presented the quorum sensing agr I gene, already
described as being common in ST22 staphylococci
[59, 60].
The most common CC isolated in our study was CC5,
present in PFGE clusters III, IV and V, and ST5 repre-
sented the second most frequent ST, after ST22. CC5 is
another common and widespread clonal complex that
includes a large number of different MRSA, some of
which pandemic [58]. Shortly after the emergence of
EMRSA-15, the New York-Japan (NY/JP) ST5-II and,
more recently, a variant of this clone, ST105-II, appeared
as the second most predominant clone in Portuguese
hospitals [20]. Recently, a high percentage of MRSA
(21.6 %) was also found in a community in Portugal,
where EMRSA-15 or related clones were the predomin-
ant ones (77.2 %), followed by NY/JP or related clones
(14.9 %) [61]. In this study, isolates belonging to CC5
presented mainly agr type II, particularly ST5, and
included both MRSA and MSSA [18].
Besides ST5 and ST105, several ST belonging to CC5
were identified, namely MSSA agrI ST6, MSSA agrI
ST72, MSSA agrI ST188, MSSA agrI ST582, MSSA agrI
ST1507, MRSA agrI ST2246 and MRSA agrII ST2599.
These less frequent ST have already been described in
Portugal [20, 61, 62], with the exception of the ST1507
and ST2599, but little information is available regarding
these ST. In fact, the only description found in the
S. aureus MLST database (http://saureus.mlst.net), re-
fers to a MRSA ST1507 isolated in 2006 in South Korea
from a foodborne source and a MRSA ST2599 isolated
from urine in 2013 in the USA. In our study the patient
from which ST2599 (CC5) was recovered, also pre-
sented another S. aureus belonging to ST105 (CC5),
being the only case where it was possible to identify
two different ST in the same patient. In the other six
cases in which the same patient showed two similar,
but not identical pulsotypes, MLST revealed that they
belonged to the same ST. Interestingly, some clones
belonging to different CC presented a higher PFGE
similarity than clones included in the same CC, as
already observed [18].
Cluster II included only one isolate, MSSA agrI ST944
(CC182). MSSA ST944 was described in Switzerland
being isolated from nasal swabs of healthy risk-free adult
carriers [63] and in China, where it was present with
high frequency in nasal carriage of healthy children in a
kindergarten [64]. In the S. aureus MLST database, a
MSSA ST944 has also been described in Norway, related
with nasal swab carriage (http://saureus.mlst.net).
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Cluster III was the most heterogeneous cluster, in-
cluding mainly MSSA agrI isolates, belonging to the
following ST: ST7 (CC7), ST8 (CC8), ST34 (CC30) and
ST45 (CC45). In fact, a previous study concerning the
population structure of MSSA in Portugal showed that
these CC were, among others, the most predominant
clonal types found between 1992 and 2011, both in the
community and hospitals settings [20].
Patients with DFI constantly attend clinical centres for
wounds healthcare, which may explain the high diversity
of pulsotypes and ST found, including the main hospital-
acquired clones present in Portugal (CC5 and CC22). It
is important to refer that several less frequent clones,
seldom described in literature and MLST database, were
also found in this study. Therefore, diabetic patients can
be important vehicles for clonal dissemination from the
hospitals into the community and contrariwise, includ-
ing less common clones.
Conclusions
To our knowledge this is one of the few reports of
staphylococci isolated from DFI that include information
about the isolates origin, virulence factors and anti-
microbial resistance profiles. Studies in DFI micro-
biology are scarce, as described recently by Zenelaj et
al. [5], and further investigation of diabetic foot
infections is urgent, allowing to adapt the therapeutic
approach of these patients to the microbiological
characteristics of the microorganisms involved.
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